Depression Among Pregnant and Breastfeeding Persons Participating in Two Randomized Trials of the Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis (PrEP) in Malawi, South Africa, Uganda, and Zimbabwe

• Published in: AIDS and behavior 2024-07, Vol.28 (7), p.2264-2275
• Main Authors: Stoner, Marie C.D., Mathebula, Florence, Sedze, Natasha, Seyama, Linly, Mohuba, Rebone, Fabiano, Zayithwa, Etima, Juliane, Young, Alinda, Scheckter, Rachel, van der Straten, Ariane, Piper, Jeanna, Noguchi, Lisa, Montgomery, Elizabeth T., Balán, Iván C.
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adult; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - therapeutic use; Breast feeding; Breast Feeding - psychology; Breastfeeding & lactation; Contraceptive Devices, Female; COVID-19; Depression - epidemiology; Depression - prevention & control; Digital video recorders; Disease prevention; Female; Health Psychology; HIV; HIV Infections - epidemiology; HIV Infections - prevention & control; HIV Infections - psychology; Human immunodeficiency virus; Humans; Infants; Infectious Diseases; Infidelity; Malawi - epidemiology; Medicine; Medicine & Public Health; Mental depression; Original Paper; Pandemics; Postpartum depression; Pre-Exposure Prophylaxis; Pregnancy; Prevalence; Prevention; Prophylaxis; Public Health; Pyrimidines - administration & dosage; Social interactions; Social support; South Africa - epidemiology; Stress; Uganda - epidemiology; Unemployment; Vagina; Young Adult; Zimbabwe - epidemiology
• ISSN: 1090-7165; 1573-3254; 1573-3254
• DOI: 10.1007/s10461-024-04321-2

Depression is associated with lower adherence to oral pre-exposure prophylaxis (PrEP) to prevent HIV, but data are not currently available on how depression may affect use of other HIV prevention methods including the dapivirine vaginal ring (DVR). We conducted a mixed methods study using data from the Microbicide Trials Network (MTN) 042/DELIVER ( n  = 558) and MTN-043/B-PROTECTED ( n  = 197) studies to describe the prevalence of depressive symptoms and explore how depressive symptoms may have influenced attitudes about use of the monthly DVR and once-daily oral PrEP tablet among pregnant and breastfeeding persons, respectively, in Malawi, South Africa, Uganda, and Zimbabwe. Eleven participants had high Edinburgh Postnatal Depression scores ≥ 10 in MTN-042/DELIVER (2%) and four participants (2%) in MTN-043/B-PROTECTED. In interviews with 9 participants who had high scores (6 DVR, 3 oral PrEP), those with depressive symptoms described overlapping stressors which were magnified by job loss and economic instability during the COVID-19 pandemic, and by experiences of pregnancy/postpartum. These participants experienced a lack of support from partners or family members, and conflict with partners related to trust, and infidelity. While we did not find evidence of a change in product adherence, there was a strong sense of commitment and motivation to use the study products for protection from HIV for participants themselves and their baby. Although lack of social support is usually an obstacle to adherence, in this study, the participants’ lives and relationships seemed to have reinforced the need for HIV prevention and motivated women to protect themselves and their babies from HIV.